



Search Q

[Advanced Search](#)

## Division of Laboratory Systems (DLS)

[DLS Home](#)



[DLS Home](#)

[About Us](#) +

[LIVD Mapping Tool for SARS-CoV-2 Tests](#)

[Strengthening Clinical Laboratories](#)

[CDC's Laboratory Outreach Communication System \(LOCS\)](#) +

[Laboratory Communicators' Network](#) +

[Free Educational Materials for Public Health and Clinical Laboratories](#)

[Competency Guidelines for Laboratory Professionals](#)

[CDC Biorepository](#)

[Biological Risk Assessment: General Considerations for Laboratories](#)

[Lab Week](#) +

[Get Email Updates](#)

# 07/21/2021: Lab Alert: Changes to CDC RT-PCR for SARS-CoV-2 Testing



**Audience:** Individuals Performing COVID-19 Testing

**Level:** Laboratory Alert

After December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only. CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives.

[Visit the FDA website](#) for a list of authorized COVID-19 diagnostic methods. For a summary of the performance of FDA-authorized molecular methods with an FDA reference panel, [visit this page](#).

In preparation for this change, CDC recommends clinical laboratories and testing sites that have been using the CDC 2019-nCoV RT-PCR assay select and begin their transition to another FDA-authorized COVID-19 test. CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses. Such assays can facilitate continued testing for both influenza and SARS-CoV-2 and can save both time and resources as we head into influenza season. Laboratories and testing sites should validate and verify their selected assay within their facility before beginning clinical testing.

[Opt in to receive updates from the CDC Laboratory Outreach Communication System \(LOCS\).](#)

**Online resources:**

- [FAQ: CDC Distribution of COVID-19 Assays](#)
- [Guidance for SARS-CoV-2 Point-of-Care Testing](#)
- [Interim Guidance for SARS-CoV-2 Antigen Testing](#)

To receive email updates about this page, enter your email address:

Email Address

[What's this?](#)

Submit

### Related Links

[Clinical Laboratory Improvement Amendments \(CLIA\)](#)

[Laboratory Training](#)

[Biosafety](#)

[Laboratory Medicine Best Practices \(LMBP\)](#)

[Clinical Laboratory Improvement Advisory Committee \(CLIAC\)](#)

- [Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-19](#)
- [Frequently Asked Questions about COVID-19 for Laboratories](#)
- [Information for Laboratories about COVID-19](#)
- [CDC COVID-19 Website](#)
- [Clinical Laboratory COVID-19 Response Weekly Calls](#)
- [CDC Laboratory Outreach Communication System \(LOCS\)](#)

If you have any questions, please contact us at [LOCS@cdc.gov](mailto:LOCS@cdc.gov).

### The Laboratory Outreach Communication System

Laboratory Outreach Communication System (LOCS) | Division of Laboratory Systems (DLS)

Center for Surveillance, Epidemiology, and Laboratory Services (CSELS)





Centers for Disease Control and Prevention (CDC)

[LOCS@cdc.gov](mailto:LOCS@cdc.gov)

[www.cdc.gov/csels/dls/locs](http://www.cdc.gov/csels/dls/locs)

Page last reviewed: July 19, 2021  
Content source: Division of Laboratory Systems (DLS)

#### HAVE QUESTIONS?

-  Visit CDC-INFO
-  Call 800-232-4636
-  Email CDC-INFO
-  Open 24/7

#### CDC INFORMATION

- About CDC
- Jobs
- Funding
- Policies
- File Viewers & Players

#### Privacy

- FOIA
- No Fear Act
- OIG
- Nondiscrimination
- Accessibility

#### CONNECT WITH CDC



U.S. Department of Health & Human Services

USA.gov

CDC Website Exit Disclaimer 